LARON SYNDROME - CLINICAL-FEATURES, MOLECULAR PATHOLOGY AND TREATMENT

被引:58
作者
LARON, Z [1 ]
KLINGER, B [1 ]
机构
[1] TEL AVIV UNIV,SACKLER FAC MED,IL-69978 TEL AVIV,ISRAEL
关键词
LARON SYNDROME; GROWTH HORMONE; INSENSITIVITY RESISTANCE; RECEPTOR; IGF-1; TREATMENT;
D O I
10.1159/000184193
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary growth hormone (GH) insensitivity (Laron syndrome) is a hereditary disease due to polymorphic defects in the GH receptor, or in the postreceptor mechanisms, leading to an inability to generate IGF-1. The clinical features and biochemical profiles are indistinguishable from isolated GH deficiency. A diagnostic feature is the lack of rise of serum IGF-1 in response to GH. In most patients growth hormone binding protein is low. Treatment of children with Laron syndrome by biosynthetic IGF-1 accelerates linear growth velocity and head circumference, reduces body fat, and stimulates kidney function.
引用
收藏
页码:198 / 202
页数:5
相关论文
共 38 条
[31]  
Laron Z, 1980, SECONDARY DIABETES S, P363
[32]  
LARON Z, 1993, ENDOCRINOLOGIST, V3, P21
[33]  
Laron Z, 1984, ADV INTERNAL MED PED, P117
[34]  
LARON Z, 1986, HUMAN GROWTH HORMONE, P163
[35]   GROWTH-HORMONE RECEPTOR AND SERUM BINDING-PROTEIN - PURIFICATION, CLONING AND EXPRESSION [J].
LEUNG, DW ;
SPENCER, SA ;
CACHIANES, G ;
HAMMONDS, RG ;
COLLINS, C ;
HENZEL, WJ ;
BARNARD, R ;
WATERS, MJ ;
WOOD, WI .
NATURE, 1987, 330 (6148) :537-543
[36]  
MAHESHWARI HG, 1993, PEDIAT AD E, V24, P160
[37]   CHEMICAL SYNTHESIS, CLONING, AND EXPRESSION OF GENES FOR HUMAN SOMATOMEDIN-C (INSULIN-LIKE GROWTH FACTOR-I) AND 59VAL-SOMATOMEDIN-C [J].
NIWA, M ;
SATO, S ;
SAITO, Y ;
UCHIYAMA, F ;
ONO, H ;
YAMASHITA, M ;
KITAGUCHI, T ;
SHIGA, Y ;
NOTANI, J ;
YAMADA, H ;
ISHII, Y ;
UEDA, I ;
TAKAGI, Y .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1986, 469 :31-52
[38]  
ROSENBLOOM AL, 1993, PEDIAT AD E, V24, P34